The debrisoquine oxidation phenotype was determined in 91 schizophrenic patients on monotherapy with different neuroleptics and in 67 untreated healthy volunteers. The prevalence of poor metabolizers of debrisoquine was significantly higher in the patients (46.2%) than in the healthy subjects (7.5%). Treatment with phenothiazine antipsychotics (chlorpromazine, levomepromazine and thioridazine) was associated with a higher debrisoquine metabolic ratio than treatment with haloperidol. On the other hand, treatment with clothiapine appeared not to interfere with debrisoquine oxidation. Oral administration of 50 mg thioridazine daily to 8 healthy subjects resulted in a marked increase in the debrisoquine metabolic ratio and 4 of them were transformed into phenotypically poor metabolizers. The results confirm the fact that phenothiazines, and to a lesser extent haloperidol, inhibit the oxidative metabolism of debrisoquine. They show also that clothiapine administration does not disturb the debrisoquine metabolic ratio.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00626371 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spectral and 3D model studies of the interaction of orphan human cytochrome P450 2U1 with substrates and ligands.
Biochim Biophys Acta Gen Subj
January 2017
UMR 8601 CNRS, University Paris Descartes, Paris Sorbonne Cité, 75270 Paris, France. Electronic address:
Background: Cytochrome P450 2U1 (CYP2U1) has been identified from the human genome and is highly conserved in the living kingdom. It is considered as an "orphan" protein as few data are available on its physiological function(s) and spectral characteristics. Its only known substrates reported so far are unsaturated fatty acids such as arachidonic acid (AA), and, more recently, N-arachidonoylserotonin (AS) and some xenobiotics related to debrisoquine (Deb) and terfenadine.
View Article and Find Full Text PDFExpression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies.
Biochim Biophys Acta
July 2015
UMR 8601 CNRS, University Paris Descartes, Paris Sorbonne Cité, 75270 Paris, France.. Electronic address:
Background: Cytochrome P450 2U1 (CYP2U1) has been identified from the human genome and is highly conserved in the living kingdom. In humans, it has been found to be predominantly expressed in the thymus and in the brain. CYP2U1 is considered as an "orphan" enzyme as few data are available on its physiological function(s) and active site topology.
View Article and Find Full Text PDFTime- and NADPH-dependent inhibition of cytochrome P450 3A4 by the cyclopentapeptide cilengitide: significance of the guanidine group and accompanying spectral changes.
Drug Metab Dispos
September 2014
Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee (M.B., F.P.G.); Merck-Serono, RBM S.p.A. Istituto di Ricerche Biomediche A. Marxer, Colleretto Giacosa, Torino, Italy (L.B., S.R.); Merck-Serono, Global Early Development, Darmstadt, Germany (H.D.); and Merck-Serono, Global Early Development, Darmstadt/Global DMPK, Grafing, Germany (A.F., D.G.)
Cilengitide is a stable cyclic pentapeptide containing an Arg-Gly-Asp motif responsible for selective binding to αVβ3 and αVβ5 integrins. The candidate drug showed unexpected inhibition of cytochrome P450 (P450) 3A4 at high concentrations, that is, a 15-mM concentration caused attenuation of P450 3A4 activity (depending on the probe substrate): 15-19% direct inhibition, 10-23% time-dependent inhibition (30-minute preincubation), and 54-60% metabolism-dependent inhibition (30-minute preincubation). The inactivation efficiency determined with human liver microsomes was 0.
View Article and Find Full Text PDFPurification and Characterization of the Human Liver Cytochromes P-450 Involved in Debrisoquine 4-Hydroxylation and Phenacetin -Deethylation, Two Prototypes for Genetic Polymorphism in Oxidative Drug Metabolism (Distlerath, L. M., Reilly, P.
View Article and Find Full Text PDFPolymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study.
BMC Med Genet
March 2012
Department of Anatomical Sciences and Neurobiology, University of Louisville, KY, USA.
Background: There are no known causes for progressive supranuclear palsy (PSP). The microtubule associated protein tau (MAPT) H1 haplotype is the major genetic factor associated with risk of PSP, with both oxidative stress and mitochondrial dysfunction also implicated. We investigated whether specific single nucleotide polymorphisms (SNPs) in genes encoding enzymes of xenobiotic detoxification, mitochondrial functioning, or oxidative stress response, including debrisoquine 4-hydroxylase, paraoxonase 1 and 2, N-acetyltransferase 1 and 2 (NAT2), superoxide dismutase 1 and 2, and PTEN-induced putative kinase are associated with PSP.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!